Abstract
-
Migraine is typically underdiagnosed and undertreated.
-
There is no cure for migraine; nevertheless there are numerous interventions that may help restore an improve life for sufferers. These measures should consider the patient in as broad an aspect as possible.
-
Triggering factors, neurogenic inflammation, vascular changes, and pain transmission should all be addressed aggressively.
-
Individualizing treatment and use of multiple modalities is essential.
Author was deceased at the time of publication.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Vos T, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163–96.
Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646–57.
Lipton RB, Scher AI, Kolodner K, et al. Migraine in the United States: epidemiology and patterns of health care use. Neurology. 2002;58(6):885–94.
Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. Cephalalgia. 1988;8(Suppl 7):1–96.
Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. Cephalalgia. 2004;24(Suppl 1):160. Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013:33:629–808.
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1545–1602.
Waters WE. Headache (series in clinical epidemiology). London: Croom Helm; 1986.
Selby G, Lance JW. Observations on 500 cases of migraine and allied vascular headache. J Neurol Neurosurg Psychiatry. 1960;47:23–32.
Silberstein SD, Lipton RB, Goadsby PJ. Headache in clinical practice. Oxford: ISIS Medical Media; 1998.
Woods RP, Iacoboni M, Maziotta JC. Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med. 1994;331:1689–92.
Moskowitz MA, Henrikson BM, Markowitz S, Saito K. Intra- and extravascular nociceptive mechanisms and the pathogenesis of head pain. In: Olsen J, Edvinsson L, editors. Basic mechanisms of headache. Amsterdam: Elsevier; 1988. p. 429.
Moskowitz MA, Cutrer FM. Sumatriptan: a receptor-targeted treatment for migraine. Annu Rev Med. 1993;44:145–54.
Peroutka SJ. The pharmacology of current antimigraine drugs. Headache. 1990;30(Suppl 1):5–11.
Weiller C, May A, Limmeroth, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995;1:658–60.
Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature. 1996;384:560–3.
Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain. 2000;89:107–10.
Burstein R, Yarnitsky D, Goor-Aryeh I, et al. An association between migraine and cutaneous allodynia. Ann Neurol. 2000;47:614–24.
Burstein R, Jukubowski M, Burstein R. Analgesic Triptan action in animal model of intracranial pain: a race against the development of central sensitization. Ann Neurol. 2004;55:27–36.
Lipton RB, Dodick D, Sadosvsky R, Kolodner K, Endicott J, Hettiarachchi J, Harrison W. A self-administered screener for migraine in primary care: the ID MigraineTM validation study. Neurology. 2003;61:375–82.
Silberstein SD. Preventive treatment of migraine: an overview. Cephalalgia. 1997;17(2):67–72.
Silberstein SD, Saper JR, Freitag FG. Migraine diagnosis and treatment. In: Silberstein SD, Lipton RB, Dalessio DE, editors. Wolff’s headache and other head pain. 7th ed. Oxford: Oxford University Press; 2001. p. 121–237.
Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia. 2002;22(7):491–512.
Diener HC, Kaube H, Limmroth V. A practical guide to the management and prevention of migraine. Drugs. 1998;56(5):811–24.
Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000a;55(6):754–62.
Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, Diener H-C, Brin MF. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache J Head Face Pain. 2010;50(6):921–36.
Gray RN, Goslin RE, McCrory DC, et al. Drug treatments for the prevention of migraine headache. technical review 2.3. Duke University: US Dept of Health and Human Services, Agency for Health Care Policy and Research; February 1999. NTIS Accession No. PB99–127953. Available at: http://www.clinpol.mc.duke.edu/.
Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM. Evidence-based guidelines for migraine headache in prevention of migraine. Neurology [serial online]. Available at: http://www.neurology.org. Accessed 25 Apr 2000.
Snow V, Weiss K, Wall E, et al. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med. 2002;137:840–9.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Graff-Radford, S.B. (2017). Migraine. In: Ferreira, J., Fricton, J., Rhodus, N. (eds) Orofacial Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-51508-3_22
Download citation
DOI: https://doi.org/10.1007/978-3-319-51508-3_22
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-51507-6
Online ISBN: 978-3-319-51508-3
eBook Packages: MedicineMedicine (R0)